Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Human chorionic gonadotropin" patented technology

Human chorionic gonadotropin (hCG) is a hormone produced by the placenta after implantation. The presence of hCG is detected in some pregnancy tests (HCG pregnancy strip tests). Some cancerous tumors produce this hormone; therefore, elevated levels measured when the patient is not pregnant may lead to a cancer diagnosis and, if high enough, paraneoplastic syndromes, however, it is not known whether this production is a contributing cause, or an effect of carcinogenesis. The pituitary analog of hCG, known as luteinizing hormone (LH), is produced in the pituitary gland of males and females of all ages.

A lateral flow chromatographic test strip and its use

The application provides a lateral flow chromatography test paper and application thereof. The lateral flow chromatography test paper comprises a quality control line and an absorption pad. The lateral flow chromatography test paper further comprises an intercept line arranged between the quality control line and the absorption pad, and the material of the intercept line is one or a mixture of two or more of gelatin, carrageenan, polyacrylamide hydrogel, polyacrylic acid hydrogel, polyvinyl alcohol hydrogel or polyvinyl alcohol-sodium alginate hydrogel solution. The lateral flow chromatography test paper can improve the sensitivity of commercial test paper strips, and can be applied to new crown antigen detection, human chorionic gonadotropin detection (HCG) and cardiac troponin detection. The lateral flow chromatography test paper provided by the application can significantly improve the sensitivity by adding a cheap hydrogel intercept line after the quality control line, has good universality, and can be widely applied to various colloidal gold method test paper detection and immunofluorescence test paper detection.
Owner:WUHAN UNIV OF SCI & TECH

A method for extracting monophasic menotropin from human urine

This invention relates to the field of biopharmaceutical technology, and particularly to a method for extracting unimodal human chorionic gonadotropin (hCG) from human urine. The method includes: loading urine from a healthy pregnant woman onto a YKW214 resin chromatography column, treating it with a washing buffer and eluent containing sodium chloride, and collecting the eluent; ultrafiltration and desalting to obtain a first ultrafiltrate; adjusting the pH and loading it onto a monoclonal antibody chromatography column with a ligand specifically binding to an HCG β subunit antibody, washing and eluting, and collecting the eluent; ultrafiltration and desalting again to obtain a second ultrafiltrate; performing virus-free filtration; adjusting the pH and loading it onto an RPC15 chromatography column, selectively removing HCG containing only the β subunit by utilizing the difference in the number of hydrophobic amino acids between intact HCG molecules and free β subunits, collecting the eluent; adding ethanol for precipitation, centrifuging, and vacuum drying to obtain unimodal hCG. This method effectively removes impurities such as free β subunits, resulting in a product with high purity, high yield, good safety, simple operation, and suitability for large-scale production.
Owner:HENAN MEDSCIENCE PHARM CO LTD

Therapeutic mRNA vaccine for malignancies

Described herein is a method for cancer immunotherapy by administering to a subject an mRNA vaccine designed to express the carbonyl terminal segment of human chorionic gonadotropin (hCG). Also described an improved adjuvant by co-administration of an antisense IL-10 molecule to shift the vaccine immune response to enhanced T-cell responses to hCG. Other embodiments relate to devices and methods for improved delivery of the mRNA vaccine and adjuvant. The intended use involves repeated administration of the vaccine components to subjects over an interval of several months in a repeated boosting strategy.
Owner:ONCOCINE LLC

System for promoting in-vitro differentiation of chicken oogonial stem cells and forming blastocysts

The invention discloses a system for promoting in-vitro differentiation of chicken oogonial stem cells and forming blastocysts, and belongs to the technical field of stem cell differentiation culture. According to the invention, retinoic acid (RA) and vitamin C (VC) are added on the basis of an oogonial stem cell culture medium to induce cells to start meiosis, and then follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG), glial cell-derived neurotrophic factor (GDNF), progesterone (P4) and rosiglitazone are further added on the basis of the culture medium containing RA and VC to promote the recovery of meiosis, so that the effect of promoting meiosis is achieved. A complete system that the chicken oogonial stem cells are differentiated in vitro and form blastocysts is creatively established by inducing formation of secondary oocytes, direct evidence is provided for in-vitro reconstruction of poultry ovum generation, and a technical basis and application prospects are provided for preservation of female germ cells and large-scale production of the chicken oocytes.
Owner:SHANDONG AGRICULTURAL UNIVERSITY

Cell culture medium for producing / preparing mesenchymal stem cell exosome

PendingCN122012386ASkeletal/connective tissue cellsCell culture mediaExosome production
The invention discloses a cell culture medium for producing / preparing mesenchymal stem cell exosomes. The cell culture medium takes DMEM (Dulbecco Modified Eagle Medium) as a basic culture medium and is added with the following components: amino acids, vitamins, inorganic salts, lipids, nucleic acid substances, an EGF (Epidermal Growth Factor), a TGF (Transforming Growth Factor), a growth promoting factor, HCG (Human Chorionic Gonadotropin) and trace elements. The mesenchymal stem cell culture medium is definite in component, free of serum components, controllable in quality and capable of being produced on a large scale, and stem cells can normally grow after being cultured in vitro. Particularly, the cell culture medium for producing / preparing the mesenchymal stem cell exosome can obtain more exosomes with higher purity under the same cell culture condition. The cell culture medium is beneficial to large-scale production of mesenchymal stem cell exosomes with good biological activity, further promotes wide application of the exosomes in medical treatment, anti-aging, beauty treatment and the like, and has good economic benefits.
Owner:SHANGHAI YINGXUNSI BIOTECHNOLOGY CO LTD